Glaxo's Advair can help lung disease - U.S. panel
WASHINGTON, May 1 (Reuters) - Company studies show GlaxoSmithKline Plc's (GSK.L)(GSK.N) high-dose Advair can reduce chronic obstructive pulmonary disease flare-ups, a U.S. advisory panel said in an 11-0 vote on Tuesday.
The U.S. Food and Drug Administration panel of outside experts earlier said data on Advair 500/50 did not show the drug helped COPD patients live longer.
((Reporting by Susan Heavey, editing by Martin Golan; Reuters Messaging: susan.heavey.reuters.com@reuters.net, Phone: 202-354-5848)) Keywords: GLAXOSMITHKLINE ADVAIR/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWBT006909










